Crocs' Q3 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance -- Shares Surge 16% Pre-Bell

MT newswire2026/10/29 13:29

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

09:29 AM EDT, 10/29/2026 (MT Newswires) -- Crocs (CROX) shares were up 16% pre-bell after it reported Q3 adjusted earnings Thursday of $3.69 per diluted share, compared with $2.92 a year earlier. Analysts surveyed by FactSet expected $3.31. Revenue for the quarter ended Sept. 30 was $1.04 billion, compared with $996.3 million a year earlier. Analysts surveyed by FactSet expected $1.0 billion. For Q4, Crocs expects adjusted EPS of $3.25 to $3.45. Analysts expect $3.11. The company also expects Q4 revenue growth of approximately 7% to 9%. For 2026, the company raised its adjusted EPS guidance to $14.45 to $14.65 from $13.70 to $14.00. Analysts expect $13.96. Crocs also raised its full-year revenue-growth outlook to about 3% from prior guidance of 1% to 2%.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12